Pacira BioSciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Pacira BioSciences (PCRX).

Price Target Range — 12 Quarters

Analyst Consensus — 11 Analysts

4Buy

7Hold

Consensus RatingOutperform# Analysts11Avg. Consensus PT$37Upside to Avg. PT+1.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 9, 2026	Truist Securities	Anish Nikhanj	Downgrade	Buy→Hold	$31→$37
Oct 9, 2026	RBC Capital	Douglas Miehm	PT Raise	Sector Perform	$25→$37
Oct 9, 2026	HC Wainwright & Co.	Douglas Tsao	Downgrade	Buy→Neutral	$38→$37
Oct 8, 2026	JP Morgan	Hardik Parikh	Upgrade	Underweight→Neutral	$37
Oct 8, 2026	Jefferies	Glen Santangelo	Downgrade	Buy→Hold	$36
Oct 8, 2026	Needham	Serge Belanger	Downgrade	Buy→Hold	—
Oct 7, 2026	Truist Securities	Les Sulewski	PT Raise	Buy	$30→$31
Sep 23, 2026	Oppenheimer	Les Sulewski	Initiate	Outperform	$32
Sep 9, 2026	Leerink Partners	Daniel Clark	Initiate	Market Perform	$28
Aug 5, 2026	RBC Capital	Douglas Miehm	PT Raise	Sector Perform	$24→$25
Aug 5, 2026	Needham	Serge Belanger	PT Raise	Buy	$32→$33
Jul 1, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$38
May 1, 2026	RBC Capital	Douglas Miehm	PT Raise	Sector Perform	$22→$24
May 1, 2026	Needham	Serge Belanger	PT Raise	Buy	$30→$32
Mar 26, 2026	Barclays	Glen Santangelo	PT Cut	Equal-Weight	$27→$25
Jan 9, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Buy	$38
Jan 9, 2026	Needham	Serge Belanger	Maintained	Buy	$30
Dec 9, 2025	Barclays	Glen Santangelo	Initiate	Equal-Weight	$27
Nov 17, 2025	HC Wainwright & Co.	Douglas Tsao	Assumes	Buy	$38
Nov 7, 2025	Truist Securities	Les Sulewski	PT Cut	Buy	$30→$28

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Truist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5

Truist Securities analyst Anish Nikhanj downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Hold and raises the price target from $31 to $36.5.

Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5

RBC Capital analyst Douglas Miehm maintains Pacira BioSciences (NASDAQ:PCRX) with a Sector Perform and raises the price target from $25 to $36.5.

Benzinga Newsdesk

This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Analysts downgraded Voya, Pacira, Genworth, and more, with price-target changes for several.

Avi Kapoor

CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday

Analysts raised targets for HOOD, SAIL, U and CRWD; cut targets for BULL, ALGN and PCRX, with PCRX downgraded to Neutral.

Avi Kapoor

PRO
HC Wainwright & Co. Downgrades Pacira BioSciences to Neutral, Lowers Price Target to $36.5

HC Wainwright & Co. analyst Douglas Tsao downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Neutral and lowers the price target from $38 to $36.5.

Benzinga Newsdesk

PRO
Jefferies Downgrades Pacira BioSciences to Hold, Announces $36 Price Target

Jefferies analyst Glen Santangelo downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Hold and announces $36 price target.

Benzinga Newsdesk

Pacira BioSciences Inc

Pacira BioSciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Truist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5

PRO
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5

This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday

PRO
HC Wainwright & Co. Downgrades Pacira BioSciences to Neutral, Lowers Price Target to $36.5

PRO
Jefferies Downgrades Pacira BioSciences to Hold, Announces $36 Price Target

People Also Watch

People Also Watch

Pacira BioSciences Inc

Pacira BioSciences Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROTruist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5

PRORBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5

This Voya Financial Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

CrowdStrike To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday

PROHC Wainwright & Co. Downgrades Pacira BioSciences to Neutral, Lowers Price Target to $36.5

PROJefferies Downgrades Pacira BioSciences to Hold, Announces $36 Price Target

People Also Watch

People Also Watch

PRO
Truist Securities Downgrades Pacira BioSciences to Hold, Raises Price Target to $36.5

PRO
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $36.5

PRO
HC Wainwright & Co. Downgrades Pacira BioSciences to Neutral, Lowers Price Target to $36.5

PRO
Jefferies Downgrades Pacira BioSciences to Hold, Announces $36 Price Target